독 Satorius invests 120 billion KRW in Incheon Songdo... "Supplying raw materials to Celltrion and Samsung Bio"

[Asia Economy Reporter Seo So-jung] German life sciences company Sartorius has decided to supply raw and subsidiary materials necessary for pharmaceutical production to Celltrion and Samsung Biologics through a facility investment worth 120 billion KRW in Songdo, Incheon.

On the 12th, Sartorius visited the headquarters of Samsung Biologics and Celltrion located in Songdo, Incheon, respectively, and signed a memorandum of understanding (MOU) for cooperation in supplying raw and subsidiary materials.

According to this agreement, Sartorius plans to stably supply raw and subsidiary materials for biopharmaceuticals such as single-use bags, cell culture media, and filters to both companies.

To this end, Sartorius will invest approximately 120 billion KRW (100 million USD) for research and development and manufacturing of key products in the biopharmaceutical process field in Songdo, including single-use bags and cell culture media.

On November 4th, Sartorius submitted a letter of intent for investment to the Incheon Free Economic Zone Authority to purchase a site of 24,333㎡ in Songdo for the construction of bioprocess product manufacturing and service facilities, aiming to complete the factory by 2022.

Founded in Germany in 1870, Sartorius is a global company that supplies research and process-related products and equipment in the life sciences field and supports related technical services.

Kim Deok-sang, CEO of Sartorius Korea Biotech, the Korean branch of Sartorius, said, “We decided to invest thanks to the rapidly developing potential of the Korean bio market, the attractiveness of Songdo as a bio cluster, and the active support of Samsung Biologics and Celltrion within the Songdo bio cluster. Through this MOU, we expect to supply products to our clients more quickly and at competitive prices.”

This content was produced with the assistance of AI translation services.